Last reviewed · How we verify
Lansoprazole - Marketed approved dose
Lansoprazole - Marketed approved dose is a Proton pump inhibitor (PPI) Small molecule drug developed by Cinclus Pharma Holding AB. It is currently in Phase 3 development for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Zollinger-Ellison syndrome.
Lansoprazole inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion.
Lansoprazole inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Zollinger-Ellison syndrome.
At a glance
| Generic name | Lansoprazole - Marketed approved dose |
|---|---|
| Sponsor | Cinclus Pharma Holding AB |
| Drug class | Proton pump inhibitor (PPI) |
| Target | H+/K+-ATPase (proton pump) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
Lansoprazole is a proton pump inhibitor (PPI) that irreversibly binds to and inactivates the H+/K+-ATPase enzyme on the secretory surface of gastric parietal cells. This blocks the final step of gastric acid production, significantly reducing both basal and stimulated acid secretion. It is used to treat acid-related gastrointestinal disorders by maintaining elevated gastric pH.
Approved indications
- Gastroesophageal reflux disease (GERD)
- Peptic ulcer disease
- Zollinger-Ellison syndrome
- Acid-related dyspepsia
Common side effects
- Headache
- Diarrhea
- Abdominal pain
- Nausea
- Constipation
- Vitamin B12 deficiency (with long-term use)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lansoprazole - Marketed approved dose CI brief — competitive landscape report
- Lansoprazole - Marketed approved dose updates RSS · CI watch RSS
- Cinclus Pharma Holding AB portfolio CI
Frequently asked questions about Lansoprazole - Marketed approved dose
What is Lansoprazole - Marketed approved dose?
How does Lansoprazole - Marketed approved dose work?
What is Lansoprazole - Marketed approved dose used for?
Who makes Lansoprazole - Marketed approved dose?
What drug class is Lansoprazole - Marketed approved dose in?
What development phase is Lansoprazole - Marketed approved dose in?
What are the side effects of Lansoprazole - Marketed approved dose?
What does Lansoprazole - Marketed approved dose target?
Related
- Drug class: All Proton pump inhibitor (PPI) drugs
- Target: All drugs targeting H+/K+-ATPase (proton pump)
- Manufacturer: Cinclus Pharma Holding AB — full pipeline
- Therapeutic area: All drugs in Gastroenterology
- Indication: Drugs for Gastroesophageal reflux disease (GERD)
- Indication: Drugs for Peptic ulcer disease
- Indication: Drugs for Zollinger-Ellison syndrome
- Compare: Lansoprazole - Marketed approved dose vs similar drugs
- Pricing: Lansoprazole - Marketed approved dose cost, discount & access